Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that ...

Novo Nordisk's diabetes drug Ozempic has been linked to a rare and serious eye condition that can cause sudden and ...

Af­ter some de­lay, the Fed­er­al Trade Com­mis­sion has ap­proved No­vo Hold­ings’ $16.5 bil­lion ac­qui­si­tion of ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

Novo Holdings has received the green light for its giant acquisition of the American pharmaceutical manufacturer Catalent, Ritzau reports.According to a stock exchange announcement, all regulatory ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...